Superluminal Medicines, based in Boston, MA, raised $120M in Series A funding to advance generative medicine.

The round was led by RA Capital Management with Insight Partners, NVentures, Gaingels, Catalio Capital Management, Eli Lilly and Cooley LLP participating.

Funds will support the clinical development of its lead program and expand small molecule drug discovery efforts targeting high-value GPCRs.

CEO Cony D’Cruz leads the company, which uses advanced biology, chemistry, and machine learning to revolutionize drug discovery.